Phase 2Update

Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T

Pancreatic cancer, Cancer

NVCRNovoCure Limited

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T
Development stage: Phase 2
Event type: Update
Indication: Pancreatic cancer, Cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 2 update for Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T in Pancreatic cancer, Cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

07/23/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided

Phase 2Update

Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T

Pancreatic cancer, Cancer

NVCRNovoCure Limited

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T
Development stage: Phase 2
Event type: Update
Indication: Pancreatic cancer, Cancer

Research summary

What is being tracked?

Development notes

07/23/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided

Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Stereotactic radiosurgery (SRS) w/ NovoTTF-200M

Optune Gio® w/ radiation therapy & temozolomide (TMZ)

Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Stereotactic radiosurgery (SRS) w/ NovoTTF-200M

Optune Gio® w/ radiation therapy & temozolomide (TMZ)